Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Sun Pharma Advanced Research Company (SPARC) is a clinical-stage pharmaceutical R&D company demerged from Sun Pharma, focused on discovering and developing novel chemical entities and new drug delivery systems, particularly in oncology and neurology. It has no meaningful commercial manufacturing base; income comes from licensing fees and milestones on out-licensed assets, so earnings are lumpy and tied to clinical trial outcomes and partnering deals.
Sun Pharma Advanced Research Company Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Sun Pharma Advanced Research Company Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 47.86 | -10.55 | -11.93 |
| Book value / share (₹) | 41.26 | -6.69 | 3.88 |
| Return on equity | 116.2% | 158.0% | -307.9% |
| Return on capital employed | 112.1% | 866.8% | -165.8% |
| Operating margin | 84.5% | -467.5% | -548.8% |
| Net margin | 82.7% | -477.2% | -512.5% |
| EBITDA | ₹1,599 Cr | ₹-323 Cr | ₹-402 Cr |
| Free cash flow | ₹-263 Cr | ₹-371 Cr | ₹-456 Cr |
| Total debt | ₹556 Cr | ₹258 Cr | ₹47 Cr |
| Debt to equity | 0.42 | -1.19 | 0.37 |
| Interest coverage | 46.5 | -37.1 | -245.3 |
| Current ratio | 2.47 | 0.07 | 1.02 |
| Shares outstanding | 32,45,00,000 | 32,45,00,000 | 32,45,00,000 |
Open the full income statement, balance sheet and cash flow for SPARC →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.